BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22105318)

  • 21. The efficacy of neoadjuvant chemotherapy in invasive bladder cancer.
    Cam K; Yildirim A; Ozveri H; Turkeri L; Akdas A
    Int Urol Nephrol; 2002; 33(1):49-52. PubMed ID: 12090338
    [TBL] [Abstract][Full Text] [Related]  

  • 22. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.
    ; ; ; ; ; ; ; ; Griffiths G; Hall R; Sylvester R; Raghavan D; Parmar MK
    J Clin Oncol; 2011 Jun; 29(16):2171-7. PubMed ID: 21502557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reasons why not all Danish patients with muscle invasive bladder cancer receive neoadjuvant chemotherapy before radical cystectomy.
    Nielsen N; Wrist Lam G; Fabrin K; Holt P; Thind PO; Jensen JB
    Scand J Urol; 2019 Aug; 53(4):213-216. PubMed ID: 31174449
    [No Abstract]   [Full Text] [Related]  

  • 24. Contemporary update on neoadjuvant therapy for bladder cancer.
    Nguyen DP; Thalmann GN
    Nat Rev Urol; 2017 Jun; 14(6):348-358. PubMed ID: 28290459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature.
    Benisovich VI; Silverman L; Slifkin R; Stone N; Cohen E
    Cancer; 1996 Jan; 77(1):160-3. PubMed ID: 8630924
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic chemotherapy for advanced bladder cancer: update and controversies.
    Garcia JA; Dreicer R
    J Clin Oncol; 2006 Dec; 24(35):5545-51. PubMed ID: 17158540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Is there an indication for adjuvant or neoadjuvant systemic chemotherapy in bladder cancer?].
    Suttmann H; Retz M; Gschwend JE; Stöckle M
    Urologe A; 2007 Oct; 46(10):1379-80, 1382-4. PubMed ID: 17805506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours.
    Sengeløv L; von der Maase H; Lundbeck F; Barlebo H; Colstrup H; Engelholm SA; Krarup T; Madsen EL; Meyhoff HH; Mommsen S; Nielsen OS; Pedersen D; Steven K; Sørensen B
    Acta Oncol; 2002; 41(5):447-56. PubMed ID: 12442921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy in bladder cancer: ready for prime time?
    Pouessel D; Gauthier H; Serrate C; Pfister C; Culine S
    J Clin Oncol; 2014 Dec; 32(36):4168-9. PubMed ID: 25385728
    [No Abstract]   [Full Text] [Related]  

  • 30. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Advances in chemotherapy of invasive bladder cancer.
    Akaza H
    Curr Opin Urol; 2000 Sep; 10(5):453-7. PubMed ID: 11005451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged remission in recurrent bladder carcinoma after chemotherapy with cisplatin.
    Coates AS; Golovsky D; Freedman A
    Med J Aust; 1981 May; 1(10):533-4. PubMed ID: 7195973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perioperative chemotherapy for bladder cancer.
    Sonpavde G; Petrylak DP
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):133-44. PubMed ID: 15990329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neoadjuvant chemotherapy for invasive bladder cancer.
    Sonpavde G; Sternberg CN
    Curr Urol Rep; 2012 Apr; 13(2):136-46. PubMed ID: 22314880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
    George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
    Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant phase II studies of modified methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer.
    Adesunloye BA
    J Clin Oncol; 2014 Dec; 32(36):4170. PubMed ID: 25385733
    [No Abstract]   [Full Text] [Related]  

  • 37. Paclitaxel and carboplatin in bladder cancer: recent developments.
    Vaughn DJ
    Eur J Cancer; 2000 Jul; 36 Suppl 2():7-12. PubMed ID: 10908842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy in the management of invasive and metastatic bladder cancer.
    Raghavan D
    Eur Urol; 1988; 14 Suppl 1():21-3. PubMed ID: 3053200
    [No Abstract]   [Full Text] [Related]  

  • 39. New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder.
    De Santis M; Bachner M
    Curr Opin Urol; 2007 Sep; 17(5):363-8. PubMed ID: 17762632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant chemotherapy for bladder transitional cell carcinoma: a new standard of care?
    Mazhar D; Ali N; Ngan S
    Future Oncol; 2007 Feb; 3(1):5-8. PubMed ID: 17280495
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.